CIC bioGUNE researchers investigate myelin in Alzheimer’s disease

Shifting the Alzheimer’s Research Paradigm

Scientists at CIC biomaGUNE in Spain are studying whether structural changes in myelin during early-stage Alzheimer’s can improve understanding of disease progression and eventually guide new diagnostic and therapeutic methods. Jordi Llop, who leads the project at the research center, notes that deteriorated myelin can make electrical communication between neurons slower and less efficient.

The research aims to determine if protecting or repairing this protective cover can help preserve the function of brain circuits impacted by the disease. However, the exact role of myelin deterioration remains an open question in neurology. Investigators are still trying to establish whether myelin breakdown acts as an initiating cause of the disease, a consequence of other cerebral changes, or a combination of both factors.

Deploying PET Imaging in Animal Models

To map and monitor these changes, the CIC biomaGUNE team employs positron emission tomography (PET) imaging alongside specialized tracers built to identify myelin-associated alterations. These non-invasive tools allow scientists to observe specific signals inside the brain.

Researchers are coupling these imaging techniques with animal model experiments. The laboratory work tests whether specific compounds can shield or restore myelin sheaths and whether those repairs correlate with better memory retention later on. The long-term goal focuses on determining whether these imaging methods can spot early brain alterations and measure how patients respond to future treatments.

Connecting Myelin Loss to Clinical Severity

This emerging hypothesis gains support from independent scientific work, though definitive causality in human patients has not yet been proven. A study published in 2026 in Alzheimer’s Research & Therapy examined data from 1,237 participants drawn from the Alzheimer’s Disease Neuroimaging Initiative.

The analysis revealed that the decline of an indicator used to approximate myelin integrity progressed alongside overall Alzheimer’s severity. In early stages, those alterations aligned with a faster subsequent accumulation of beta-amyloid. In later phases, the changes coincided with a wider presence and greater extension of tau protein.

Additional experimental studies using animal models have similarly demonstrated that myelin dysfunction can promote beta-amyloid accumulation. These findings reinforce scientific interest in mapping exactly where myelin degradation fits into the chronological chain of the disease.

Evaluating Preclinical Limits and Human Trials

While this line of inquiry provides a path that complements traditional strategies targeting beta-amyloid and tau, it comes with strict limitations. Researchers are looking past mere neuronal survival to evaluate the quality of the connections that link brain cells together.

Despite these investigative steps, no clinical evidence currently shows that repairing myelin can prevent, halt, or reverse Alzheimer’s disease in humans. The CIC biomaGUNE project remains in the preclincial research phase. Before any therapeutic application in patients can be planned, the approach must first demonstrate that protecting this neural insulation produces consistent, safe cognitive benefits.